Skip to main content
. 2010 Oct 26;89(3):614–622. doi: 10.1093/cvr/cvq338

Figure 2.

Figure 2

ET-1 effects on O-GlcNAcylated-proteins are not observed when cells are previously transfected with OGT siRNA, incubated with an OGT inhibitor or with an ETA antagonist. Treatment with (A) the OGT inhibitor (ST045849) or the ETA antagonist (atrasentan) as well as (B) transfection with the OGT siRNA decrease vascular O-GlcNAcylation, upon ET-1 incubation for 24 h in comparison with VSMCs that were incubated with vehicle (DMSO) or control siRNA for 24 h. On the top, western blot image of O-GlcNAcylated-proteins; on the bottom, corresponding bar graphs showing the relative O-GlcNAcylated-proteins after normalization to β-actin expression (n = 6). Results are presented as mean ± SEM in each experimental group (n = 6). *P < 0.05 vs. vehicle (DMSO); #P < 0.05 vs. control siRNA.